RxDoctor Payments Data

Felix Torres Cabrera, MD

Internal Medicine · Livingston, LANPI 1295708899

Payments from drug & device makers

$1,492in general payments, 2019–2025

Across 93 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$438
  • Lilly USA, LLC$170
  • Novo Nordisk$137
  • Boehringer Ingelheim$118
  • Merck$73
  • Abbott$72
  • plus $485 from 16 others

What the payments were for

  • Food & beverage$1,48499%
  • Education$81%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,492 in reported general payments places this provider in the 70th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$27,797
Medicare patients
102
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin152$123,141
OzempicSemaglutide70$78,070
TrulicityDulaglutide36$59,399
JanuviaSitagliptin Phosphate82$58,218
MounjaroTirzepatide19$20,022
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$13,840
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$11,406
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$6,656
VascepaIcosapent Ethyl12$4,003
Atorvastatin Calcium537$3,724
Albuterol Sulfate HfaAlbuterol Sulfate68$2,332
CreonLipase/Protease/Amylase12$2,259
Potassium Chloride89$1,951
Sucralfate12$1,906
Amlodipine Besylate360$1,888

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$118$123,141152 claims
Lilly USA, LLCTrulicity, Mounjaro$170$79,42155 claims
Novo NordiskOzempic$137$78,07070 claims
MerckJanuvia$73$58,21882 claims
GSKTrelegy Ellipta, Anoro Ellipta$438$25,24639 claims
AbbVieCreon, Synthroid$36$3,78230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Livingston

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →